GlassScriptPhysician profile
Esam M Obed
NPI 1568422350
$8,275.71
in general payments reported to CMS, 2019-2025
37 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $1,082 · 2021: $1,319 · 2022: $1,182 · 2023: $1,065 · 2024: $1,082 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,199.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,192.75 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,087.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $793.70 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $792.40 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Actelion Pharmaceuticals US, INC. | $578.11 | 2019-2023 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $415.65 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $401.81 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $393.60 | 2019-2025 | Lifevest |
| Pfizer INC. | $339.32 | 2019-2025 | |
| Amarin Pharma, INC. | $294.85 | 2019-2021 | |
| Abbott Laboratories | $273.03 | 2019-2025 | Aveir, Esprit, Hi-Torque Versacore |
| Novo Nordisk INC | $176.14 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.99 | 2020-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $142.90 | 2024 | Arcalyst |
| Abiomed | $125.68 | 2019-2023 | Impella |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esam Obed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.